Elan-J&J Deal Breaches Biogen Tysabri Deal: Court
A federal court has found that Ireland-based drug manufacturer Elan Corp. PLC violated a nine-year collaboration agreement with Biogen Idec Inc. for the development and marketing of multiple sclerosis medication Tysabri...To view the full article, register now.
Already a subscriber? Click here to view full article